Lindahl has acted as a legal advisor to Sedana Medical AB (publ) in connection with the company’s change of listing from Nasdaq First North Growth Market to the Nasdaq Stockholm main list. Trading in the company’s shares commenced on 25 January 2023. The closing price for the company’s share on the first trading day was SEK 27.06 per share, equivalent to a value of approximately SEK 2.7 billion for all shares in Sedana Medical.
Sedana Medical is a medical technology and pharmaceutical company founded in 2004. The company is based in Danderyd, outside Stockholm, and its operations include development, marketing and sale of the medical device Sedaconda ACD and its accessories, as well as the Sedaconda (isoflurane) sedation medication.
Lindahl’s team consisted mainly of Ola Svanberg, Monica Lagercrantz, Mikael Nagy and Ebba Meyer-Lie (capital markets and public M&A), Mårten Lindberg and Asta Schulz (IP/Tech), Matilda Jusslin (employment) and Anna Romell Stenmark (tax).